Cidara Therapeutics, an hVIVO client, has announced positive topline results for its Phase 2b study of candidate CD388 in seasonal influenza. CD388 previously demonstrated influenza illness prevention efficacy in a challenge study conducted by hVIVO, and the demonstration of positive results in the Phase 2b field study – drawing on a range of hVIVO services – demonstrates the power of hVIVO’s vertical and horizontal service offering in our view. We maintain our investment thesis, anticipating ne ....